UNSPSC 51313708: Isothipendyl hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19N3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 953AP1LBV8, chemically known as 10h-pyrido(3,2-b)(1,4)benzothiazine-10-ethanamine, n,n,alpha-trimethyl- but more generally known as isothipendyl hydrochloride, which bears US NIH Compound Identifier 3781. European Medicines Agency schedules Isothipendyl hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02807MIG.

UNSPSC 51313708 Isothipendyl hydrochloride is a Commodity code that in recent state and local activity names pharmaceutical products and drug-related supplies procured to support community health, emergency response, and pharmacy benefit programs. The solicitations tagged under this code reflect a much broader pattern of state and local governments purchasing generic pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work spans routine pharmaceutical sourcing for state and local healthcare delivery, emergency opioid-response supplies, and exploratory procurement to redesign pharmacy benefit program structures through direct-to-manufacturer contracting.

Recent activity is concentrated in the South, Midwest, and Southwest. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with responses due by July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a market-intelligence phase preceding formal RFP development. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products to be distributed across participating state and local government facilities in Minnesota and Oregon, with responses due March 26, 2026. The code shows active procurement across health departments, pharmacy benefit administrators, and cooperative purchasing consortia, with vendors required to meet cGMP certification, FDA compliance, and DSCSA drug supply chain security standards.